# Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

Source: https://onco.cc/trials/nct07056777/  
OnCo record `nct07056777` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Oxaliplatin, Capecitabine and Leucovorin (folinic acid) in advanced solid tumours, run by Zhejiang Doer Biologics Co., Ltd., now recruiting.

## Summary

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer is a phase 1/2 interventional study registered as NCT07056777 by Zhejiang Doer Biologics Co., Ltd., with 186 participants planned, started 2025-03-25 and due to reach its primary completion in 2027-04-30. Interventions recorded: DR30206, Oxaliplatin, Capecitabine, Calcium Folinate, 5-FU and Irinotecan (CPT-11).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07056777
- Phase: 1/2
- Setting: A Phase Ib/IIa Clinical Trial Evaluating the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Tumors
- Sponsor: Zhejiang Doer Biologics Co., Ltd.
- Enrolled: 186

## Sources

- ClinicalTrials.gov NCT07056777: https://clinicaltrials.gov/study/NCT07056777

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)

---
JSON: https://onco.cc/api/v1/entities/nct07056777.json